Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical research and therapy development.

Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge technologies in individual products and fully integrated platforms. Allele utilizes proprietary non-integrating cellular reprogramming methods to develop cell therapy and enable drug discovery through the use of human and non-human primate iPS cells, cGMP-grade human iPS cells and their derivatives. With additional expertise in genome modification and unique cell-based fluorescence sensors/reporters, Allele provides advanced cell and assay development solutions. Allele also has developed a wide variety of advanced research tools including superior fluorescent proteins, genotyping kits, and camelid antibodies that have been validated for co-immunoprecipitation, histology, and flow cytometry. The Company has also been a leader in the RNAi field with its patents in Pol III promoter-driven siRNA, shRNA, and miRNA.



If you are committed to making a significant difference within the scientific community and believe in career advancement, we invite you to learn more about our business groups, our products and plans for the future. Please email: info@allelebiotech.com


  • 2024- Cellular Logistics, Allele Biotech Enter into Collaboration to Develop Regenerative Medicine
  • 2021 – Allele Biotechnology, Pfizer, Inc., and BioNTech (SE and US) resolved in a mutually satisfactory manner the patent infringement lawsuit brought by Allele concerning mNeonGreen.
  • 2020- Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines
  • 2020– Received RadX grant (NIH funded) for our project “Rapid Antigen Test Kit for SARS-CoV-2 Using Nanoantibodies”
  • 2019- Allele Biotechnology and SCM Lifescience Sign a Joint Research and Development Agreement to Develop iPSC-based Diabetes Treatment
  • 2018- Allele received granting of patents on generating mRNA-iPSCs in the US, EU, and Japan, among other jurisdictions.
  • 2017- Received NIA/NIH funding to develop nanoantibodies against a novel dementia-related target with collaborators in Dr. Huaxi Xu's lab at Sanford Burnham Prebys Medical Discovery Institute
  • 2017- Published an original research article in Applied Immunohistochemistry & Molecular Morphology demonstrating the utility of modified nanoantibodies "nAb Plus", in immunohistochemistry
  • 2016- Received NHLBI/NIH grant to develop a large-scale stem cell production
  • 2016- Received additional VC funding to develop iPSC-derived cell therapies in the fields of diabetes, spinal injury, and other diseases
  • 2016- Published a protocol for cGMP production of iPSCs in Current Protocols in Stem Cell Biology
  • Hyperlink Example See More